Cardiol Therapeutics (NASDAQ:CRDL) announced Tuesday that it has surpassed 50% patient enrollment in its pivotal Phase III MAVERIC trial, a major step toward bringing the first non-immunosuppressive oral therapy to patients suffering from recurrent pericarditis.
AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo have announced the first patient has been dosed in the TROPION-Lung17 Phase 3 trial, a landmark study that marks the first time an antibody-drug conjugate (ADC) is being evaluated using a prospective, AI-powered biomarker in lung cancer.
Sight Sciences (NASDAQ:SGHT), a leader in interventional eyecare technologies, released preliminary fourth-quarter 2025 results on Jan. 13, showing a return to growth driven by its interventional dry eye business.
Treace Medical Concepts (NASDAQ:TMCI) shares are under scrutiny after the bunion-correction specialist reported preliminary fourth-quarter revenue that reflected a nearly double-digit decline.
Armata Pharmaceuticals (NYSE:ARMP) is poised to become the first company to advance a bacteriophage candidate into a Phase 3 clinical trial, following a positive End-of-Phase 2 (EOP2) response from the U.S. Food and Drug Administration (FDA).
Cardinal Health (NYSE:CAH) raised its fiscal year 2026 earnings outlook Tuesday, citing rapid acceleration in its specialty pharmaceutical business and a successful navigating of federal drug pricing changes.
Kestra Medical Technologies (NASDAQ:KMTS) has announced a strategic collaboration and exclusive co-development agreement with Biobeat Technologies to integrate advanced hemodynamic monitoring into its cardiac recovery platform.
Aclarion (NASDAQ:ACON), a commercial-stage healthcare technology company, has closed a $10.4 million common-stock-only financing, significantly bolstering its balance sheet as it seeks to transform the diagnosis of chronic low back pain.
AbbVie (NYSE:ABBV) has entered into a voluntary three-year agreement with the Trump administration, pledging a massive $100 billion investment in U.S.-based research, development, and manufacturing over the next decade.
Visionary Holdings (NASDAQ:GV) shares are under pressure after the company’s 2025 annual report revealed a significant revenue contraction and mounting liquidity concerns.
Argenx SE (NASDAQ:ARGX) shares are in focus after the U.S. Food and Drug Administration accepted a supplemental Biologics License Application for Vyvgart with Priority Review, potentially expanding the drug's reach to a difficult-to-treat subset of patients with generalized myasthenia gravis (gMG).
Biodesix (NASDAQ:BDSX) shares surged in early Monday trading after the lung diagnostics firm reported preliminary 2025 revenue that eclipsed its own upwardly revised guidance.
The company’s focus on high-margin lung cancer testing and a strategic expansion into primary care drove a 41% revenue spike in the fourth quarter.
